Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016326495> ?p ?o ?g. }
Showing items 1 to 98 of
98
with 100 items per page.
- W2016326495 endingPage "15" @default.
- W2016326495 startingPage "9" @default.
- W2016326495 abstract "Objectives – To evaluate the impact of different dosages of topiramate (TPM) add-on to stable antiepileptic therapy for refractory partial epilepsy in adults. Material and methods – Pooled intention-to-treat analysis of six similarly designed double-blind, placebo-controlled trials, including 481 patients treated with doses of TPM 200, 400, 600 and 800 mg/day, and 265 patients receiving placebo. Results – Seizures were reduced by ≥50% from baseline in 41% of TPM-treated patients and 15% of placebo-treated patients (P < 0.001); 5 and 0.8%, respectively, were seizure-free (P < 0.003). TPM was significantly better than placebo regardless of gender, age, baseline seizure rate as well as number and type of concomitant antiepileptic drugs. Efficacy was statistically significant in favour of TPM at all dose levels: at least 50% seizure reduction was achieved in 40% of patients with 200 mg, 41% with 400 mg, 44% with 600 mg and 41% with 800 mg TPM when compared with 15% with placebo (P ≤ 0.001 for each dosage arm vs placebo). The median reduction in monthly seizure frequency was 38%, 42%, 45% and 38% vs 8%, respectively (P ≤ 0.001). Moreover, response to TPM was significantly superior to placebo at each of the dose levels tested for most of the baseline variables. The total percentage of withdrawals increased with the dosage, and the withdrawals caused by adverse events increased from 3% with placebo to 7% with 200 mg TPM (not significant vs placebo), 15% with 400 mg TPM (P = 0.08), 16% with 600 mg TPM (P = 0.002) and 15% with 800 mg TPM (P = 0.003). Conclusion – The efficacy of TPM add-on in partial epilepsy is consistent across efficacy endpoints and independent of study population characteristics. The response at 200 mg TPM is similar to the response at higher doses, but as drop-outs caused by adverse events are more frequent above the 200 mg dose, this pooled analysis supports that 200 mg daily is a good target dose for add-on therapy in most patients with partial epilepsy, showing an excellent balance between efficacy and tolerability." @default.
- W2016326495 created "2016-06-24" @default.
- W2016326495 creator A5031602893 @default.
- W2016326495 creator A5037632361 @default.
- W2016326495 creator A5069259299 @default.
- W2016326495 creator A5085400242 @default.
- W2016326495 creator A5087176280 @default.
- W2016326495 date "2003-06-16" @default.
- W2016326495 modified "2023-09-27" @default.
- W2016326495 title "A pooled analysis of adjunctive topiramate in refractory partial epilepsy" @default.
- W2016326495 cites W1975482049 @default.
- W2016326495 cites W2006821779 @default.
- W2016326495 cites W2020042979 @default.
- W2016326495 cites W2032090906 @default.
- W2016326495 cites W2043242122 @default.
- W2016326495 cites W2070403944 @default.
- W2016326495 cites W2080494081 @default.
- W2016326495 cites W2117449343 @default.
- W2016326495 cites W2129745199 @default.
- W2016326495 cites W2171332093 @default.
- W2016326495 cites W4236676256 @default.
- W2016326495 cites W4253837878 @default.
- W2016326495 doi "https://doi.org/10.1034/j.1600-0404.2003.00113.x" @default.
- W2016326495 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12807387" @default.
- W2016326495 hasPublicationYear "2003" @default.
- W2016326495 type Work @default.
- W2016326495 sameAs 2016326495 @default.
- W2016326495 citedByCount "25" @default.
- W2016326495 countsByYear W20163264952012 @default.
- W2016326495 countsByYear W20163264952013 @default.
- W2016326495 countsByYear W20163264952014 @default.
- W2016326495 countsByYear W20163264952016 @default.
- W2016326495 countsByYear W20163264952020 @default.
- W2016326495 countsByYear W20163264952023 @default.
- W2016326495 crossrefType "journal-article" @default.
- W2016326495 hasAuthorship W2016326495A5031602893 @default.
- W2016326495 hasAuthorship W2016326495A5037632361 @default.
- W2016326495 hasAuthorship W2016326495A5069259299 @default.
- W2016326495 hasAuthorship W2016326495A5085400242 @default.
- W2016326495 hasAuthorship W2016326495A5087176280 @default.
- W2016326495 hasConcept C118552586 @default.
- W2016326495 hasConcept C121332964 @default.
- W2016326495 hasConcept C126322002 @default.
- W2016326495 hasConcept C142424586 @default.
- W2016326495 hasConcept C142724271 @default.
- W2016326495 hasConcept C162156334 @default.
- W2016326495 hasConcept C197934379 @default.
- W2016326495 hasConcept C204243189 @default.
- W2016326495 hasConcept C204787440 @default.
- W2016326495 hasConcept C27081682 @default.
- W2016326495 hasConcept C2775858608 @default.
- W2016326495 hasConcept C2777683783 @default.
- W2016326495 hasConcept C2778186239 @default.
- W2016326495 hasConcept C2779384505 @default.
- W2016326495 hasConcept C42219234 @default.
- W2016326495 hasConcept C535046627 @default.
- W2016326495 hasConcept C71924100 @default.
- W2016326495 hasConcept C87355193 @default.
- W2016326495 hasConceptScore W2016326495C118552586 @default.
- W2016326495 hasConceptScore W2016326495C121332964 @default.
- W2016326495 hasConceptScore W2016326495C126322002 @default.
- W2016326495 hasConceptScore W2016326495C142424586 @default.
- W2016326495 hasConceptScore W2016326495C142724271 @default.
- W2016326495 hasConceptScore W2016326495C162156334 @default.
- W2016326495 hasConceptScore W2016326495C197934379 @default.
- W2016326495 hasConceptScore W2016326495C204243189 @default.
- W2016326495 hasConceptScore W2016326495C204787440 @default.
- W2016326495 hasConceptScore W2016326495C27081682 @default.
- W2016326495 hasConceptScore W2016326495C2775858608 @default.
- W2016326495 hasConceptScore W2016326495C2777683783 @default.
- W2016326495 hasConceptScore W2016326495C2778186239 @default.
- W2016326495 hasConceptScore W2016326495C2779384505 @default.
- W2016326495 hasConceptScore W2016326495C42219234 @default.
- W2016326495 hasConceptScore W2016326495C535046627 @default.
- W2016326495 hasConceptScore W2016326495C71924100 @default.
- W2016326495 hasConceptScore W2016326495C87355193 @default.
- W2016326495 hasIssue "1" @default.
- W2016326495 hasLocation W20163264951 @default.
- W2016326495 hasLocation W20163264952 @default.
- W2016326495 hasOpenAccess W2016326495 @default.
- W2016326495 hasPrimaryLocation W20163264951 @default.
- W2016326495 hasRelatedWork W1964352248 @default.
- W2016326495 hasRelatedWork W2006587801 @default.
- W2016326495 hasRelatedWork W2016326495 @default.
- W2016326495 hasRelatedWork W2051430123 @default.
- W2016326495 hasRelatedWork W2061077838 @default.
- W2016326495 hasRelatedWork W2105422910 @default.
- W2016326495 hasRelatedWork W2117449343 @default.
- W2016326495 hasRelatedWork W2128757265 @default.
- W2016326495 hasRelatedWork W2171332093 @default.
- W2016326495 hasRelatedWork W2350878894 @default.
- W2016326495 hasVolume "108" @default.
- W2016326495 isParatext "false" @default.
- W2016326495 isRetracted "false" @default.
- W2016326495 magId "2016326495" @default.
- W2016326495 workType "article" @default.